Browsing Tag
PF Prism C.V.
1 post
Alembic Pharmaceuticals gains three USFDA approvals in oncology and neurology, but can these launches offset U.S. pricing pressures?
Alembic Pharmaceuticals secures USFDA approvals in oncology and neurology, but can these launches drive U.S. revenue growth? Read the full analysis.